u/DadStrengthDaily

A study published July 1 in The Lancet, from the NCD Risk Factor Collaboration, pooled 110 national surveys covering close to a million people across seven countries from 1990 to 2024. They compared blood pressure and non-HDL cholesterol between adults with obesity and adults at a normal weight, then tracked how that gap moved over three decades. For adults over 40, it has nearly closed. In the heaviest group, BMI 35 and up, older adults with obesity now have non-HDL numbers about the same as their normal-weight peers, sometimes a little lower.

The authors credit wider, more intensive statin and blood pressure treatment in heavier people, not diet or weight loss. Older US work says the same thing. Between the early 1990s and late 2000s, average total cholesterol fell from 216 to 197 while the share of adults on a lipid-lowering drug went from 1.6 to 12.5 percent, and researchers estimated the drugs, not diet, accounted for about half the drop.

Two guideline changes did a lot of this work, which is the part I'd want anyone tracking their own lipids to know. In 2013 the ACC/AHA dropped the old cholesterol targets and switched to overall risk, and that single move made about 12.8 million more adults statin-eligible overnight. Heavier people crossed the line more often, because obesity drags the risk score up through blood pressure, glucose, and lipids. Then in March 2026 they bolted a 30-year risk estimate onto the 10-year one, built to catch younger people whose 10-year number looks harmless but whose lifetime risk is high. One analysis put that expansion near 20 million more Americans.

One thing to be clear about: this is non-HDL and blood pressure only. It says nothing about Lp(a), and it doesn't touch the metabolic problems that come along with excess weight. Real harm reduction on two numbers, not a green light.

Curious what this sub thinks, especially anyone who watched their own non-HDL or ApoB drop on a statin without much change on the scale. Did the number move the way you expected?

The Medicare GLP-1 Bridge is live as of today. If you're on Part D or a Medicare Advantage drug plan and you qualify, the obesity GLP-1s drop to a flat $50/month through the end of 2027. I fought my own insurance for months to get on a GLP-1, so I've been watching this one closely. Three things are tripping people up in the first hours:

1. Zepbound only counts if it's the KwikPen. The single-dose vials and pens (including the cheaper LillyDirect vials) are not covered. If your script says vials, it won't ring up at $50. Get it rewritten for the KwikPen.

2. Nothing happens until the prior auth is approved. It couldn't even be filed before today. If the pharmacy quotes the old price, the usual cause is no PA on file yet, not a coverage gap. Don't pay the cash price out of panic.

3. The $50 doesn't count toward your out-of-pocket max. The Bridge runs outside the normal Part D flow, so it won't help you hit your annual cap, and there's no low-income subsidy here even if you normally get one.

On which drug to ask for: they're all $50, so price isn't the lever. Foundayo is the daily pill if you won't inject, Zepbound has shown the most weight loss if you're fine with a weekly shot, Wegovy is the middle option and comes as a shot or a tablet.

Not medical advice, I'm not a doctor. Talk to your prescriber about your own situation.

Full day-one write-up with the eligibility tiers and the appeal steps if you get denied

I kept seeing the claim that VO2 max is the single best predictor of how long you'll live, always bolted to the same number: the least fit 20% have about five times the death rate of the fittest people. It's real, but it's a magic trick, and once I saw how it's built I stopped being impressed.

In the big Cleveland Clinic study ([Mandsager 2018](https://pubmed.ncbi.nlm.nih.gov/30646252/)), "elite" doesn't mean the top fifth of people. It means the top 2.3%, the 98th percentile and up. Compare the least-fit fifth against that thin sliver and of course you get a five-times ratio. It isn't the comparison a normal person should plan around.

Put every group on equal footing instead, worst fifth against best fifth, and the number gets smaller but a lot more useful: about [1.85x for all-cause death](https://pubmed.ncbi.nlm.nih.gov/23130161/) (Barlow's Cooper Center data). Still one of the strongest things you can move. Just not five times.

However, what jumped out at me wasn't the top end, it was how much you get just from leaving the bottom. Going from the least-fit fifth to merely below average buys you more than going from good to great. The steep drop is leaving the floor, and the curve flattens after that. So the fifty-year-old who has done nothing doesn't need to chase an elite number. He needs to stop being sedentary.

Couple of caveats I should add. Most of these papers aren't even measuring a true lab VO2 max, they're estimating fitness from how long you last on a treadmill. Useful, but not the same thing. And the weird one is [income](https://pubmed.ncbi.nlm.nih.gov/25322291/): look at raw gaps and it's actually wider than fitness (around 3.8x). It only shrinks once you adjust, because a lot of it runs through fitness, weight, and smoking anyway. Money isn't a separate dial, it shows up as the other stuff.

The part I'd actually act on is simpler. [Guys who went from unfit to fit](https://pubmed.ncbi.nlm.nih.gov/7707596/) cut their death rate by about 44%. That beats arguing about elite percentiles.

For what it's worth, I rowed a hard 2k this week, 7:28.8, which works out to a VO2 max around 42 by the rowing estimate. Above average for 53, nowhere near elite, and that's exactly the boring, good place to be and slowly improve from.

Full write-up with the charts

I'm fair-skinned and spent most of my life barely wearing sunscreen. When the FDA approved bemotrizinol this month, the first new US sunscreen filter in about 20 years (https://www.fda.gov/news-events/press-announcements/fda-expands-sunscreen-options-first-time-20-years), I figured I'd finally read the actual evidence. Some of it wasn't what I expected.

Melanoma diagnoses went up about sixfold since the 1970s, but the death rate barely moved (Welch, NEJM 2021 (https://doi.org/10.1056/NEJMsb2019760)). Which mostly means we got a lot better at finding it, not that it got more deadly. One paper put roughly 60% of melanomas now diagnosed in white people down to overdiagnosis (Adamson, JAMA Dermatology 2022 (https://doi.org/10.1001/jamadermatol.2022.0139)), real under a microscope but stuff that would never have hurt you. It still kills 8,000+ a year though, so I'm not saying skip sunscreen. Just that you don't have to be scared into it.

The SPF number turned out to be mostly a cushion for how little anyone actually puts on. Most people use a quarter to half of the lab dose, so your SPF 50 is realistically closer to a 14 (Petersen, 2014 (https://doi.org/10.1111/phpp.12099)). Reapplying beats chasing a bigger number on the bottle.

I went in half-expecting the usual mineral-good, chemical-bad story and didn't really find it. Both kinds absorb UV. And the "chemical filters show up in your blood" thing was about a testing cutoff, not proven harm. The FDA itself said it wasn't a reason to stop using sunscreen.

Honestly the only thing I changed was checking the UV index in the weather app instead of guessing by season. I'm in Boston, and a sunny June day here hits 7. January it's a 1.

Full write-up with the sources

I take ezetimibe, a $20 generic, and it gets my ApoB where it needs to be. Tom Dayspring, the lipidologist a lot of us learned this stuff from and Peter Attia's go-to lipid guy, can't take it. Or a statin. I think his case is worth knowing about, because it shows how ugly this gets when the cheap drugs are off the table.

He posted last week that he's "one of them": one of the rare people with genuine, serious statin muscle injury. Not the vague aches that usually turn out to be nocebo. Statins gave him myoglobinuria, muscle protein in the urine, the early edge of rhabdo. Ezetimibe gives him severe myalgias too. So the two cheap, first-line drugs are both off the table for him.

And he needs them. He has a coronary calcium score over 300 and documented coronary disease. This is the kind of patient those aggressive LDL targets are supposed to catch. He just can't get there the normal way, so he has been on a PCSK9 inhibitor (Repatha) basically since they came out.

The part that shocked me: when he first needed the PCSK9i, his insurer refused, because he had not had a heart attack yet. In his telling, they wanted him to have his first heart attack, then they would cover it, if he survived. Then this spring he tried to add bempedoic acid and got denied again, because his LDL was "too good," under 70. He only qualified after the new 2026 guideline dropped the high-risk LDL target to 55, at which point his 64 flipped from too-good to not-good-enough and the same drug went through. His body did not change. A number in a guideline did.

I'm not saying everyone needs a PCSK9 inhibitor or bempedoic acid. Most people reach goal on a statin and a little ezetimibe and should stop there. But real statin intolerance is rare and real, it is not the same as the nocebo effect, and if you are in that small group you can end up arguing for your only option against a system that reads your good numbers as a reason to say no. If that is the fight for the guy who wrote the lectures, it is worth knowing what it looks like for the rest of us.

If you want the receipts, the full write-up has his actual tweets, his lab panel, and the clip where he tells the insurance story on Simon Hill's podcast: https://dadstrengthdaily.com/cholesterol-expert-cant-take-statins/?utm\_source=reddit&utm\_medium=social&utm\_campaign=dayspring-statins

I've spent my career in machine learning, so most "AI predicts your death" headlines don't move me. This one did, and it matters to anyone here who has ever been told their heart "looks fine."

The setup: the only number really used to predict sudden cardiac death is ejection fraction, how well the heart squeezes, measured on an echo. Below about 35% you become a defibrillator candidate. The catch is that most people who die suddenly have a normal ejection fraction. In one Oregon study (https://pubmed.ncbi.nlm.nih.gov/16545646/), only about a third of sudden-death victims would ever have qualified for a defibrillator. For more than half of men (https://pubmed.ncbi.nlm.nih.gov/12831814/), the arrest is the first sign of any heart trouble at all.

A team at UC Berkeley (new paper in Nature (https://www.nature.com/articles/s41586-026-10674-6)) trained a model on hundreds of thousands of routine ECGs from a region of Sweden, linked to death records. In a sealed test set, it flagged about 2% of patients at roughly 7% per year risk of sudden death, against a background rate near 0.5%. Of that high-risk group, 86% would not have been caught by ejection fraction.

Why I didn't wave it off:

- They locked away 40% of the data before any analysis and didn't open it until the paper was accepted. Accuracy went up on that sealed set, not down, which is the opposite of overfitting. This is excellent ML rigor!
- It held up with no retraining on hospital data from the US and Taiwan, recorded on different machines.
- They ran a built-in negative control: the model was near useless at flagging deaths from non-rhythm causes (lung, brain), so it learned something specific to the electrical fault, not a vague "this person is sick" signal.

Instead of leaving it a black box, they built a second, generative model to morph a low-risk ECG into a high-risk one and watch what changed. Out came a never-before-described slur in one lead (aVL) that traced back to diffuse scarring (fibrosis) in the heart muscle, a known setup for fatal rhythms. That scarring was sitting on MRIs some of these patients already had, but it hadn't surfaced in their clinical notes.

The caveats matter, so here they are. You cannot get this test, it has not been shown to save a single life yet, and the randomized trial that would prove a defibrillator helps these people is still hypothetical. The prediction is solid; the scar mechanism is a strong lead, not settled.

What is actually actionable today is the unglamorous stuff that moves risk: know your blood pressure and your ApoB, get unexplained fainting or a racing heart looked at instead of shrugging it off, and find out whether anyone in your family died young and suddenly. A normal echo is not a clean bill of electrical health.

Full DSD write-up, with the chart and the actual ECG signal the model found

A buddy of mine has been sober for years. He does the meetings, has a sponsor, the whole program. And he still gets the cravings, the low background "noise" that never fully shuts off. AA got him sober. It didn't quiet the cravings.

The most promising new thing aimed at exactly that noise is a GLP-1. A couple of recent trials suggest semaglutide can lower drinking and craving, and for someone years into recovery who is still white-knuckling it, that might be the best shot yet at turning the volume down. Fair caveats up front: it's off-label for drinking, it's reduction and not abstinence, and it's not a cure. But it's the first thing in a while aimed at the craving instead of the willpower.

My buddy has been on the Wegovy pill for a month and so far reports promising results. He had replaced the booze with a nightly ritual of 2 or three bottles of sugary root beer. He hated that new habit but couldn’t kick it. On Wegovy he suddenly stopped it.

Here's what surprised me even more while reading into it. We've had FDA-approved medications that cut alcohol cravings since 1994, and almost nobody gets them. Naltrexone, a daily pill that blunts the reward from drinking, has solid trial data: treat about a dozen people and one who would have gone back to heavy drinking doesn't. Acamprosate helps hold abstinence. Vivitrol is a monthly shot for people who can't keep a daily pill going. The American Psychiatric Association and the VA both recommend them.

And still, only about 2% of people with alcohol use disorder get a medication in a given year. Count every kind of help and fewer than 1 in 12 get any treatment at all.

The reasons are cultural more than scientific. Addiction care grew up walled off from regular medicine, so the doctor you actually see rarely brings it up. And the abstinence-only culture can treat a pill as just swapping one drug for another. My buddy did the hardest version of this for years, and as far as I know no one ever mentioned that a prescription might take the edge off.

If you or someone close to you went through treatment for drinking, were medications ever actually on the table? Or was it abstinence-or-nothing?

Full write-up (the 90-year arc, from AA to naltrexone to GLP-1s, with the evidence and the caveats)

A buddy of mine has been sober for years. He does the meetings, has a sponsor, the whole program. And he still gets the cravings, the low background "noise" that never fully shuts off. AA got him sober. It didn't quiet the cravings.

The most promising new thing aimed at exactly that noise is a GLP-1. A couple of recent trials suggest semaglutide can lower drinking and craving, and for someone years into recovery who is still white-knuckling it, that might be the best shot yet at turning the volume down. Fair caveats up front: it's off-label for drinking, it's reduction and not abstinence, and it's not a cure. But it's the first thing in a while aimed at the craving instead of the willpower.

My buddy has been on the Wegovy pill for a month and so far reports promising results. He had replaced the booze with a nightly ritual of 2 or three bottles of sugary root beer. He hated that new habit but could not kick it. On Wegovy he suddenly stopped it.

Here's what surprised me even more while reading into it. We've had FDA-approved medications that cut alcohol cravings since 1994, and almost nobody gets them. Naltrexone, a daily pill that blunts the reward from drinking, has solid trial data: treat about a dozen people and one who would have gone back to heavy drinking doesn't. Acamprosate helps hold abstinence. Vivitrol is a monthly shot for people who can't keep a daily pill going. The American Psychiatric Association and the VA both recommend them.

And still, only about 2% of people with alcohol use disorder get a medication in a given year. Count every kind of help and fewer than 1 in 12 get any treatment at all.

The reasons are cultural more than scientific. Addiction care grew up walled off from regular medicine, so the doctor you actually see rarely brings it up. And the abstinence-only culture can treat a pill as just swapping one drug for another. My buddy did the hardest version of this for years, and as far as I know no one ever mentioned that a prescription might take the edge off.

If you or someone close to you went through treatment for drinking, were medications ever actually on the table? Or was it abstinence-or-nothing?

Full write-up (the 90-year arc, from AA to naltrexone to GLP-1s, with the evidence and the caveats)

A new DocsWhoLift episode finally gave me the framing for something I had been circling for weeks. Spencer and Karl Nadolsky sat down with the Barbell Medicine doctors on peptides, and it put words to it. Peptides are having a moment, but the two ends of the craze look nothing alike.

One end is the blockbuster. Retatrutide is an Eli Lilly triple-receptor agonist, and in the TRIUMPH-1 Phase 3 trial the top dose hit about 28% body weight loss over 80 weeks, near 30% in the severe-obesity group. That is gastric-bypass territory from a weekly shot. The FDA should approve it around 2027. Thousands of Americans are not waiting. There is already a grey market that takes credit cards and posts discount codes.

I am on Lilly’s Zepbound and I own Lilly stock, so I am about as friendly to this drug as a person gets. I still would not touch the grey-market version. No labs, no titration, and the vial is a coin flip. One analysis of 6,441 grey-market peptide samples found over 40% failed dose or purity, and 156 contained none of the labeled compound at all. The trial data is real. What is in the unapproved vial may not be.

The other end is stranger. BPC-157 is not a pharma project. It traces to one scientist in Croatia, Predrag Sikiric, who started chasing it as a medical student in the 1970s, and his lab has produced most of the research since. The following swears it gives near-Wolverine healing for torn tendons and bad knees. After fifty years it still has no completed large-scale human trial. Three were started and all three were terminated early, none published.

I looked into it for a personal reason. I have an aneurysm in my aorta, and people kept telling me to inject something that supposedly rebuilds blood vessels. Nobody could tell me whether it would help or hurt me. Not the discoverer, not the testing chemists, not the FDA’s own documents. I still do not have an answer. I did not inject it.

The Nadolskys’ point was simple: pick your standard first. Say what you would need to see before you put a needle in. Theirs is a real trial in real people, not a plausible mechanism, not rat data. By that bar retatrutide is almost there and BPC-157 is nowhere close. Both get injected anyway, because demand is running years ahead of proof.
It gets weirder July 23 and 24, when the FDA’s compounding committee votes on whether pharmacies can legally make BPC-157 and a dozen other peptides. A compound with no completed human trial could become something your pharmacy mixes on request.

Where do you draw your own line? FDA approval, human trial data, a clean third-party test on the actual vial? And has anyone here been told no by a doctor on one of these and gone the grey-market route anyway?

Longer versions I wrote, plus the episode:
• Retatrutide and the grey market that got there first: https://dadstrengthdaily.com/retatrutide-grey-market-inflection/
• The BPC-157 evidence hunt (the aneurysm piece): https://dadstrengthdaily.com/bpc-157-everyone-is-sure-the-evidence-is-empty/
• The DocsWhoLift x Barbell Medicine episode that kicked this off: https://youtu.be/2EUOkQPcM_0

I read two stories this week that turned out to be the same story, and I can't stop thinking about how differently they end.

The first is damning. Lunchables was developed at Oscar Mayer in the 1980s, back when a cigarette company, Philip Morris, owned it. Philip Morris ran a committee whose whole job was to move methods from its tobacco labs into its food labs. One of those methods: a rival tobacco review had concluded that Marlboro's real genius was "getting the guilt out of the product." So the company ran the same play on lunch and rolled out Low-Fat Lunchables, built to keep guilty parents from walking away. In 2023 a reformulated version nearly became a federal school lunch for 30 million kids, until Consumer Reports found lead in all 12 kits it tested and the school versions came back saltier than the ones on store shelves.

That part is easy to be angry about. Then I went looking at the actual evidence, and it got messier fast.

The scariest ultra-processed food numbers, the ones about early death and dementia, come almost entirely from observational studies, which can show that heavy UPF eaters get more disease but struggle to prove the food is the cause. The "58% higher dementia risk" stat that made headlines actually failed the study's own trend test. The number the authors could not call statistically reliable is the one that went viral.

Then the part that really got me. One of the papers making the skeptical case, showing that overall diet quality predicts health more consistently than how "ultra-processed" your diet is, was co-written by the same researcher who dug up the Lunchables documents. The people building the case against this food are the ones finding that the label is a clumsy tool.

The best controlled evidence, Kevin Hall's NIH ward study and a 2025 follow-up, does show a real effect, but a modest one, and it points at energy density and hyper-palatability. Food engineered to be eaten fast and in volume, not the number of factory steps. Which is close to what Philip Morris was tuning for forty years ago.

So I stopped sorting groceries into clean and unclean. Frozen broccoli, canned beans, and the protein bar in my gym bag are all processed and all fine. What I keep less of is the stuff built to be overeaten.

Do you track "ultra-processed" as a category, or do you ignore the label and watch specific things like sugar, sodium, energy density, and fiber? And did the cigarette-company history change how you read a label?

Full DSD write-up

A study presented at ENDO 2026 pulled NIH All of Us records linked to Fitbit data and tracked 753 adults with obesity, mean age about 52, before and after they started a GLP-1 (semaglutide, liraglutide, dulaglutide, or tirzepatide). After starting, daily steps fell from about 5,047 to 4,487 (roughly 11% fewer), and moderate-to-vigorous activity dropped from 28 to 22 minutes a day (about 21% less). The declines were largest in men and in people with joint or muscle pain, and nothing in the data suggested the weight loss pushed activity up.

Caveats: conference abstract, not peer-reviewed; retrospective and observational, so no causal claim; Fitbit-wearers self-select; and the "men declined most" finding is a subgroup of a mostly-female cohort. Signal, not verdict.

Being lighter lowers the energy cost of moving, so the physics should make activity easier, not harder. Yet steps fell. A bioRxiv preprint this year (in mice, not peer-reviewed) points at why: semaglutide suppressed voluntary wheel running, and when motivation was measured directly with a progressive-ratio task, the drugged mice worked less hard for wheel access. They were not too weak or underfed to run, they were less motivated to, with changes in nucleus accumbens dopamine, the same reward circuitry these drugs act on to quiet food-seeking. If that translates, GLP-1s may turn down the drive to move the way they turn down the drive to eat.

On the other side of it, Lundgren et al. (NEJM 2021) randomized people who had just lost weight to a GLP-1 (liraglutide), exercise, or both, and the combination held the loss better than the drug alone. So the move is to keep activity in deliberately while the drug handles appetite.

For what it's worth as an n=1 against the trend: I'm on Zepbound, down about 170 lb, and everyday movement got easier for me, not harder. But I know that's one anecdote against a population signal.

Has anyone here tracked their own steps or activity before versus after starting? Did it drop, hold, or climb?

Full write-up with the chart and sources: https://dadstrengthdaily.com/do-glp1s-make-you-move-less/?utm\_source=reddit&utm\_medium=social&utm\_campaign=glp1-move-less

I'm 53, down about 170 pounds, I lift in the garage every weekday, and my bloodwork is the best it has ever been. And I can still scroll for ten minutes through transformations and race medals and sub-three-hour marathons and come away feeling like I'm quietly failing at something everyone else figured out. The honest word for it is inferior. It's imposter syndrome wearing gym clothes.

The thing that actually fixed my head was a number I could check on myself. There's a natural ceiling on how much muscle a man can carry without drugs, measured as fat-free mass index, which is just lean mass scaled to your height. In a 1995 study of athletes, only 1 of 74 drug-free guys ever crossed an FFMI of 25, while the steroid users routinely landed well past it. So 25 is roughly the wall for a natural man, and most of us never come close.

My last DEXA: 6 foot 3, 209 pounds, around 15 percent body fat. That puts my FFMI near 22, already in the top tenth of men, with real room left before I'd hit a ceiling I'm never actually going to reach. The lean, shredded, huge-all-year physiques that were making me feel small are often sitting at 26 or higher, in a category that's partly pharmacology the caption never mentions. I was reading my slower, softer-in-January progress as a personal failure when I was racing a baseline that, for a lot of those guys, doesn't exist without a needle.

The other half of it is that the feed deletes the middle. About a tenth of a percent of Americans finish a marathon in a given year, and most adults don't hit even 150 minutes of activity a week. You're not seeing a normal range of men. You're seeing the far right tail of the curve on a loop and comparing your Tuesday to it.

And the part that should take the pressure off the most: nearly all of the health payoff comes from going from doing nothing to doing something. If you train at all, you've already banked the part that moves your odds the most. The returns above that are real but shrinking, and the impossible standards are built around that thin top slice.

So I'm not going to train harder out of inadequacy, and I'm not pushing my TRT dose to chase a look (I'm on 120 mg a week for measured low T, watched by my doctor, and I have an aortic aneurysm, so more is never a casual decision). I'm going to keep doing the boring repeatable thing and stop grading my real, good life against a leaderboard built from outliers and chemistry.

The chart is where I actually land on the curve, and seeing it did more for me than any workout. Happy to get into the FFMI math, the DEXA, or the dose.

Full write-up: https://dadstrengthdaily.com/im-in-the-best-shape-of-my-life-and-the-internet-still-makes-me-feel-like-im-losing/

I'm 53. Eighteen months ago I weighed 373 pounds. I've lost about 170 since, a little under half of what I weighed, and I'm posting it here because this sub actually cares about the markers, not just the scale. I've put the before-and-after photo, my dose-and-weight chart, and my lipid panel below.

I tried to run it like a project instead of just hoping. I tracked body composition with DEXA so I'd know whether I was losing fat or muscle, ran my lipids regularly, and logged resting heart rate and rowing times.

The dose chart surprised me, and it might help anyone here who assumes you have to climb to the top. I never reached 15 mg. Most of the weight came off at 5 and 10 mg, and once it was coming off steadily I stopped going up.

What the drug actually did was quiet the food noise. That constant background hum about the next meal and the second helping went quiet in the first couple of weeks, and that was the thing I'd been failing to out-willpower for twenty years. But it did not do the training. The shot lowers your appetite, it does not row the meters or lift the weight or get the protein in. I had to build that part, and DEXA was how I checked I was actually keeping muscle instead of just shrinking.

The markers are the part I'm proudest of, more than the before-and-after. My LDL went from 131 to 60, my ApoB landed at 62, and my resting heart rate and rowing times both came down. I was losing weight and training and eating better all at once, so I won't pretend I can credit any single piece, but the cardiovascular numbers moved further than I expected.

If you're staring down a big number and wondering whether it's worth starting, the honest version is that the drug made the deficit possible and the work did the rest. Happy to answer anything about the dosing, the DEXA, or the lipid panel.

Full write-up with all three charts and the dose breakdown: https://dadstrengthdaily.com/how-i-lost-170-pounds-after-50/

I'm 53. Eighteen months ago I weighed 373 pounds, and I've lost about 170 of them on tirzepatide. I tried to treat my own cut like a study instead of just watching the scale, so I tracked body composition with DEXA, ran lipids regularly, and logged resting heart rate and rowing times. Obvious caveat first: this is n=1 and badly confounded, because I started resistance training and fixed my diet at the same time I started the drug, so I can't cleanly separate drug effects from training effects. A couple of things stood out that I'd want this sub's take on.

The dose-response was the first surprise. I never reached the 15 mg top dose. Most of the weight came off at 5 and 10 mg, and once I was losing steadily I stopped escalating. What got me is that those doses seemed to do most of the work on appetite, and I never felt like I needed to push to 15. Maybe that's just me, but I'm curious whether the trial data shows other people getting most of the benefit before the top dose.

The body composition piece is the one I cared about most. Weight loss on these drugs isn't all fat, and the lean-mass loss is the part that worries me at my age. So I used DEXA rather than the scale to check whether I was actually losing fat or just getting smaller, and I paired the drug with resistance training and high protein specifically to bias the loss toward fat and hold onto muscle.

I can't tell how much of the muscle I held onto was the lifting and the protein versus anything from the drug itself. That's why the myostatin work like apitegromab catches my eye.

The cardiometabolic markers moved more than I expected. My LDL went from 131 to 60 with an ApoB of 62, and my resting heart rate and rowing times improved over the same window. Again, I was losing weight, training, and eating better all at once, so I'm not pinning the lipid change on the drug, but the size of the move was bigger than I'd have guessed from weight loss alone.

The drug's real lever, as far as I can tell, is appetite. It cut mine enough that the deficit finally became sustainable, and the body composition and fitness mostly tracked with the training I could actually stick to. I'm posting the data because I'd like to know what people closer to the research make of the dose question and the lean-mass question.

Full write-up with the dose chart, the DEXA breakdown, and the lipid panel: https://dadstrengthdaily.com/how-i-lost-170-pounds-after-50/

I'm 53. Eighteen months ago I weighed 373 pounds. The before photo that gets me is one my five-year-old took when I wasn't even trying to be in the frame. Today I'm a little over 200, so that's roughly 170 pounds gone, a little under half of what I weighed. I finally wrote the whole thing down, and I figured this sub would want the honest version instead of the highlight reel.

First, the part people here will recognize. The shot quieted the food noise. That constant low hum of thinking about the next meal, the second helping, the drive-thru on the way home, it went quiet within the first couple of weeks. That was the unlock for me. I'd tried to out-discipline that noise for twenty years and lost every time. Tirzepatide didn't hand me willpower, it turned down the volume on the thing I'd been spending all my willpower fighting.

The dose part surprised me, and it might matter to some of you climbing the ladder. I never reached 15 mg. Most of the loss happened at 5 and 10 mg. I kept bracing for the day I'd need the 15mg top dose and it just never came, so I stopped chasing it. Your body may be different, but "more is always better" wasn't true for me. See the chart above for the progression.

The drug gets too much credit and too much blame. It did not do the fitness work. It quiets your appetite, it does not row the meters or lift the weight or hit the protein. I started rowing, then lifting, and I tracked it with DEXA instead of just the scale so I could actually see whether I was losing fat or muscle. My resting heart rate dropped, my rowing times came down, and I got my ApoB down into the 60s. None of that came out of a pen.

So if you're early in this and the shot feels like it's doing everything, that's normal, the appetite change really is that dramatic. For me the real work started after the appetite settled down. I had more time and more bandwidth, and I put it into rowing, lifting, and eating like I meant it. A lot of that was showing up on mornings I didn't want to.

Happy to answer anything about dosing, the training, or the parts that were harder than they look.